NCT03146858View on ClinicalTrials.gov

Prolonged Enoxaparin In Primary Percutaneous Coronary Intervention; A Pilot Pharmacodynamic Study

PHASE4CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 25, 2017

Primary Completion Date

December 30, 2017

Study Completion Date

March 30, 2018

Conditions
Primary Percutaneous Coronary Intervention
Interventions
DRUG

Enoxaparin

Enoxaparin is an anticlotting treatment that targets the other aspect of clot formation known as the coagulation cascade. Enoxaparin or an alternative is recommended as a single does to support PPCI procedure.

Trial Locations (1)

S5 7AU

Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield

All Listed Sponsors
lead

Sheffield Teaching Hospitals NHS Foundation Trust

OTHER

NCT03146858 - Prolonged Enoxaparin In Primary Percutaneous Coronary Intervention; A Pilot Pharmacodynamic Study | Biotech Hunter | Biotech Hunter